

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVAL PACKAGE FOR:**

**APPLICATION NUMBER**

**21-372**

**Administrative Documents**

**13.0 Patent Information Pursuant to 21 C.F.R. § 314.53**

The following is provided in accordance with the Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(b)(1):

TRADE NAME:	To be determined
ACTIVE INGREDIENT:	palonosetron hydrochloride
STRENGTH(S):	0.25 mg
DOSAGE FORM:	Injectable solution

In accordance with 21 C.F.R. § 314.53, the following information is provided for each United States patent that claims the drug product that is the subject of this NDA, a drug substance that is a component of such drug product, or a method of using such drug product, and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product:


PATENT NUMBER:	5,202,333
DATE OF EXPIRATION:	13 April 2010
TYPE OF PATENT:	Drug substance, drug product (composition and formulation), and method of use <i>inter alia</i> for the prevention of chemotherapy-induced nausea and vomiting
NAME OF PATENT OWNER:	Syntex (U.S.A.) LLC

The undersigned declares that U.S. Patent Number 5,202,333 covers the drug substance palonosetron, formulations and/or compositions of palonosetron, and/or methods of using palonosetron. The drug product palonosetron is the subject of this NDA for which approval is being sought.


The undersigned certifies that the exclusive right and license to make, have made, develop, register, market, distribute, and sell palonosetron under U.S. Patent Number 5,202,333 is granted by the owner of the patent, Syntex (U.S.A.) LLC, to the applicant of this NDA, Helsinn Healthcare SA, under a licensing agreement between Syntex (U.S.A.) LLC and Helsinn Healthcare SA dated 23 June 1998.




Dario Ceriani  
Senior Manager, Regulatory Affairs  
Helsinn Healthcare SA



Date



Matteo Missaglia  
Director, Legal Affairs  
Helsinn Healthcare SA



Date

EXCLUSIVITY SUMMARY for NDA # 21-372 SUPPL # N/A  
Trade Name Aloxi™  
Generic Name palonosetron HCl injection  
Applicant Name Helsinn Healthcare S.A. HFD- 180  
Approval Date July 25, 2003

**PART I: IS AN EXCLUSIVITY DETERMINATION NEEDED?**

1. An exclusivity determination will be made for all original applications, but only for certain supplements. Complete Parts II and III of this Exclusivity Summary only if you answer "YES" to one or more of the following questions about the submission.

a) Is it an original NDA? YES/ X/ NO /    /

b) Is it an effectiveness supplement? YES /    / NO / X/

If yes, what type(SE1, SE2, etc.)?

c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "NO.")

YES / X/ NO /    /

d) Did the applicant request exclusivity?

YES /    / NO / X/

e) Has pediatric exclusivity been granted for this Active Moiety?

YES /    / NO / X/

**IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS ON Page 9.**

2. Has a product with the same active ingredient(s), dosage form, strength, route of administration, and dosing schedule previously been approved by FDA for the same use? (Rx to OTC Switches should be answered No - Please indicate as such).

YES /    / NO / X/

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON Page 9.

3. Is this drug product or indication a DESI upgrade?

YES /\_\_\_/ NO /x/

IF THE ANSWER TO QUESTION 3 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON Page 9 (even if a study was required for the upgrade).

**PART II: FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES**  
(Answer either #1 or #2, as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.

YES /\_\_\_/ NO /x/

IF THE ANSWER TO QUESTION 1 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.